Alimera Sciences (NASDAQ:ALIM) Downgraded by StockNews.com to Hold

StockNews.com downgraded shares of Alimera Sciences (NASDAQ:ALIM) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning.

Separately, Maxim Group assumed coverage on Alimera Sciences in a research report on Monday, March 25th. They issued a buy rating and a $10.00 target price on the stock.

Alimera Sciences Stock Performance

Alimera Sciences stock opened at $3.68 on Tuesday. Alimera Sciences has a fifty-two week low of $1.56 and a fifty-two week high of $4.38. The company has a debt-to-equity ratio of 1.40, a quick ratio of 2.31 and a current ratio of 2.39. The company has a 50 day moving average price of $3.73 and a 200-day moving average price of $3.65. The company has a market capitalization of $192.65 million, a PE ratio of -1.70 and a beta of 1.18.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.09). The firm had revenue of $26.31 million during the quarter, compared to the consensus estimate of $25.10 million. Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. During the same quarter in the prior year, the business posted ($0.54) earnings per share. As a group, equities analysts forecast that Alimera Sciences will post 0.03 earnings per share for the current year.

Hedge Funds Weigh In On Alimera Sciences

A number of large investors have recently bought and sold shares of ALIM. AIGH Capital Management LLC purchased a new position in Alimera Sciences in the 3rd quarter valued at about $7,355,000. Stonepine Capital Management LLC acquired a new position in shares of Alimera Sciences during the 3rd quarter valued at about $12,349,000. Finally, Worth Venture Partners LLC acquired a new position in Alimera Sciences in the 3rd quarter valued at about $1,840,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).